Literature DB >> 8100489

Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries.

E D Santoian1, J E Schneider, M B Gravanis, M Foegh, N Tarazona, G D Cipolla, S B King.   

Abstract

BACKGROUND: Restenosis is mediated by uncontrolled neointimal growth at the site of coronary angioplasty. Angiopeptin is an octapeptide analogue of somatostatin that has been shown to decrease the experimental intimal hyperplasia associated with vascular injury in rats and rabbits. The study purpose was to determine if angiopeptin inhibits the development of intimal hyperplasia in normolipemic swine coronary arteries after overstretch-balloon injury. METHODS AND
RESULTS: Overstretch-balloon injury was performed in normolipemic swine coronary arteries using a 3.5-mm angioplasty balloon. Treated animals received angiopeptin (50 micrograms/kg) 1 hour before and at the time of balloon injury. Angiopeptin was administered at 100 (micrograms/kg)/day SQ in two divided doses for 14 days. Animals were killed at 14 and 28 days (2 weeks after cessation of angiopeptin) after balloon injury. Treatment animals were compared with control animals receiving balloon injury alone. Angiopeptin significantly limited the experimental intimal hyperplasia estimated by the maximal intimal thickness and residual lumen (lumen area/lumen area+intimal area) compared with controls.
CONCLUSIONS: Angiopeptin inhibits the development of intimal hyperplasia in swine coronary arteries after balloon injury. The beneficial effect was detectable 2 weeks after cessation of angiopeptin therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100489     DOI: 10.1161/01.cir.88.1.11

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

Review 1.  Cardiac valve surgery in the octogenarian.

Authors:  R Prêtre; M I Turina
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

2.  Equity in access to exercise tolerance testing, coronary angiography, and coronary artery bypass grafting by age, sex and clinical indications.

Authors:  A Bowling; M Bond; D McKee; M McClay; A P Banning; N Dudley; A Elder; A Martin; I Blackman
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

3.  A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit.

Authors:  Natalie K Schiller; Alvin M Timothy; Harmeet S Aurora; I-Li Chen; David H Coy; William A Murphy; Donald L Akers; Vivian A Fonseca; Philip J Kadowitz; Dennis B McNamara
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

4.  Variability in treatment advice for elderly patients with aortic stenosis: a nationwide survey in The Netherlands.

Authors:  B J Bouma; J H van der Meulen; R B van den Brink; A E Arnold; A Smidts; L H Teunter; K I Lie; J G Tijssen
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

5.  The effect of the somatostatin analogue lanreotide on the prevention of urethral strictures in a rabbit model.

Authors:  H L Andersen; B U Duch; H Gregersen; J B Nielsen; H Ørskov
Journal:  Urol Res       Date:  2003-02-08

6.  High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; H A Neil; P C Adams
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

7.  Chronic coronary artery disease: drugs, angioplasty, or surgery?

Authors:  C S Rihal; S Yusuf
Journal:  BMJ       Date:  1996-02-03

Review 8.  How should we manage symptomatic aortic stenosis in the patient who is 80 or older?

Authors:  D C Sprigings; J C Forfar
Journal:  Br Heart J       Date:  1995-11

9.  Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation.

Authors:  M Edner; K Caidahl; L Bergfeldt; B Darpö; N Edvardsson; M Rosenqvist
Journal:  Br Heart J       Date:  1995-09

Review 10.  Pharmacological approaches to the prevention of restenosis after coronary angioplasty.

Authors:  M Hamon; E Lécluse; J P Monassier; G Grollier; J C Potier
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.